1) What are the two obstacles for successful engraftment of exogenous HSCs? Can we resolve them and how? 2) What're the
Posted: Tue Jul 12, 2022 1:22 pm
1) What are the two obstacles for successful engraftment of exogenous HSCs? Can we resolve them and how?
2) What're the nonspecific injury to other tissues and life-long complications that bone marrow transplantation or HSC transplantation can cause? Please use the reference articles that were cited in this article to address this question.
3) What're the previous evidence and experiments led authors to use anti-ckit antibodies and CD47 antagonist to deplete HSC in mice or humans?
4) Please explain figure 1a, b, c, and d using your own words. Is there anything you would suggest the authors to improve regarding their work in figure 1?
5) Use layman terms to explain what is happening in figure 2c? Why two of the 24 hours post-injection time points at figure 2d come back up? Explain.
6) Use your own words to explain figure 3.
7) What're the objectives of figure 4? Are these data consistent and predictive for bedside utilization?
8) What's re the objectives of figure 5? Are these experiments necessary and useful for bedside utilization? C) Can CD47 antagonists be useful for something else? Explain and give examples
2) What're the nonspecific injury to other tissues and life-long complications that bone marrow transplantation or HSC transplantation can cause? Please use the reference articles that were cited in this article to address this question.
3) What're the previous evidence and experiments led authors to use anti-ckit antibodies and CD47 antagonist to deplete HSC in mice or humans?
4) Please explain figure 1a, b, c, and d using your own words. Is there anything you would suggest the authors to improve regarding their work in figure 1?
5) Use layman terms to explain what is happening in figure 2c? Why two of the 24 hours post-injection time points at figure 2d come back up? Explain.
6) Use your own words to explain figure 3.
7) What're the objectives of figure 4? Are these data consistent and predictive for bedside utilization?
8) What's re the objectives of figure 5? Are these experiments necessary and useful for bedside utilization? C) Can CD47 antagonists be useful for something else? Explain and give examples